Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

This study has been terminated.
(Funds for this project have been spent, and it is thereby terminated.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT00720096
First received: July 21, 2008
Last updated: December 13, 2013
Last verified: December 2013

July 21, 2008
December 13, 2013
July 2008
October 2009   (final data collection date for primary outcome measure)
  • Assess Feasibility [ Time Frame: 1 year, 2 months ] [ Designated as safety issue: No ]
    Number of patients meeting 3 week feasibility window which was set as the benchmark.
  • Interpret Genomic Array [ Time Frame: 1 year, 2 months ] [ Designated as safety issue: No ]
    Number of patients with biopsiable tumor in sufficient quantity and quality that will result in an interpretable genomic array.
Determine response rate of array directed chemotherapy. [ Time Frame: Dependant upon results ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00720096 on ClinicalTrials.gov Archive Site
Response Rate [ Time Frame: 1 year, 2 months ] [ Designated as safety issue: No ]
Determine response rate of array directed chemotherapy (as defined as the proportion of patients achieving complete or partial responses with a predictive score ? 0.5 for either chemotherapy). As well as evaluate the accuracy of the chemosensitivity profiles for differentiating doxorubicin and topotecan responsive cancers. Due to the limited sample size the interpretation is limited. Results data for this outcome is not posted.
Overall response rate, duration of patient response. Refine methodologies for full genome expression profiling in a clinical trial; evaluate the accuracy of chemosensitivity profiles for differentiating doxorubicin and topotecan responsive cancers. [ Time Frame: Dependent upon results ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
A Pilot Prospective Trial Of Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan In Recurrent Or Persistent Ovarian Cancer Within 12 Months Of Platinum-Based Chemotherapy

This pilot study will help us to determine the success of using a special technique called microarray technology to examine cancer genes in order to predict how individual women will respond to one of two therapies, liposomal doxorubicin or topotecan, and which will be more effective in treating ovarian cancer that has returned (recurrent ovarian cancer). We believe that this study may lead to a means by which microarray technology can predict the most effective treatment decision, based on the genetic characteristics of her tumor tissue, for a woman with recurrent ovarian cancer.

Another purpose of this study is to determine how quickly a woman with recurrent ovarian cancer will respond to treatment (treatment response rate) and to evaluate the accuracy of the genomic predictions.

Recent data suggest that microarray technology can predict a patient's response to chemotherapy; this has not yet been proven in a forward-looking study which is why we are conducting this research.

Patients who take part in the study will have an initial visit and undergo a CT guided core biopsy. Using tissue from a CT guided core biopsy, microarray analysis will be performed to help predict which of the two drugs appears to be better suited to individual genomic factors. The results will result in being assigned to treatment with either liposomal doxorubicin or topotecan.

Patients who receive liposomal doxorubicin - IV chemotherapeutic treatment will occur 3 times, 28 days apart, weeks 1,5,and 9. At each of these visits patients will be evaluated and have blood work to check their liver tests and electrolytes. Every 8 weeks patients will have a radiologic evaluation of their tumor.

Patients who receive topotecan - IV chemotherapeutic treatment will occur 4 times, 21 days apart, weeks 1,4,7, and 10. At each of these visits patients will be evaluated and have blood work to check levels of liver tests and electrolytes. Every 8 weeks patients will have a radiologic evaluation of their tumor.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Ovarian Cancer
  • Drug: Liposomal Doxorubicin
    Liposomal Doxorubicin 40 mg/m2 q 28 days
    Other Name: Doxil
  • Drug: Topotecan
    1. Topotecan (daily x 5 days of a 21 day cycle)
    2. Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)
    Other Name: Hycamtin
  • Experimental: Liposomal Doxorubicin
    Liposomal Doxorubicin - Chemotherapy single agent systemic.
    Intervention: Drug: Liposomal Doxorubicin
  • Experimental: Topotecan
    Topotecan - Chemotherapy single agent systemic.
    Intervention: Drug: Topotecan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
4
October 2009
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Must have history of histologically or cytologically confirmed epithelial ovarian cancer with recurrence.
  • Must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral computed tomography CT) scan.
  • May have had only 2 prior chemotherapy regimens, with at least one regimen containing platinum, and disease recurrence or progression occurring between 0 to 12 months (1 to 365 days)from the platinum-containing regimen. Patients who have been treated with consolidation treatment are allowed and the consolidation will not be considered a separate regimen. Hormonal therapy and immunotherapy will not be considered a prior chemotherapy regimen. Hormonal therapies given to treat the patient's cancer should be stopped at least 30 days prior to dosing on this trial. Typical low-dose hormone replacement therapy to treat postmenopausal symptoms may be continued at the treating physician's discretion.
  • Life expectancy >6 months.
  • ECOG performance status 2 or less (Karnofsky 60%).
  • Must have normal organ and marrow function as defined below:

    • leukocytes 3,000/microL
    • absolute neutrophil count 1,500/ microL
    • platelets 100,000/microL
    • total bilirubin ≤1.5 X institutional upper limit of normal(ULN) aspartate aminotransferase [AST(SGOT)]/alanine aminotransferase [ALT(SGPT)] ≤2.5 X ULN creatinine within normal institutional limits OR creatinine clearance 60mL/min/1.73m2 for patients with creatinine levels above institutional normal
  • Ability to understand and willingness to sign a written informed consent document
  • Measurable disease on CT must be considered amenable to biopsy by Core methods (core biopsy may be radiographically or non-radiographically performed). Potential ability to obtain core material must be reviewed by Principal Investigator (PI) and/or his designates prior to enrollment.
  • Must consent to biopsy as part of enrolling into trial.
  • Patients with reproductive potential must use an adequate contraceptive method (e.g. abstinence, intrauterine device, oral contraceptives, barrier device with spermicide or surgical sterilization) during treatment and for three months after completing treatment.
  • Must have a Multiple Gated Acquisition (MUGA) scan or 2-d echocardiogram indicating an ejection fraction of > 50% or institutional standards within 42 days prior to first dose of study drug. The method used at baseline must be used for later monitoring.

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not version 13, 01/10/08 MCC 15042 16 recovered from adverse events due to agents administered more than 4 weeks earlier.
  • May not be receiving any other investigational agents concurrently.
  • Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to liposomal doxorubicin or topotecan.
  • Myocardial infarction within 6 months. History of cardiac disease, with New York Heart Association Class II or greater, or clinical evidence of congestive heart failure.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Women who are pregnant.
  • Women who are breastfeeding should discontinue breastfeeding.
  • Human Immunodeficiency Virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions and increased toxicity.
  • Patients may have had no other malignancies in the prior 5 years other than non-metastatic, locally-controlled, non-melanomatous cutaneous cancers.
  • Patients who have received radiation to more than 25% of marrow-bearing areas.
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00720096
MCC-15042, NFGC 12-12990-01-29
Yes
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Department of Defense
Principal Investigator: Robert M. Wenham, M.D., M.S. H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP